| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Division of Thoracic Diseases and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn.
2 From the Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minn.
3 From the Division of Anatomic Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minn.
We describe the clinical presentation, pulmonary function tests, chest radiograph, and computed tomography findings, response to hormonal treatment, and duration of survival of nine patients with pulmonary involvement in tuberous sclerosis complex with follow-up over an average of 17 years (range, 1 to 35 years) since diagnosis. All patients were female, and the average age at onset of symptoms was 16 years (range, 3 months to 39 years); pulmonary symptoms did not develop until an average age of 33 years (range, 22 to 46 years). There was an average delay of 8 years before the correct diagnosis was made. The most common presenting clinical features were seizures, pneumothorax, bleeding into a renal angiomyolipoma, dyspnea, and typical skin changes. Pulmonary function tests commonly demonstrated obstruction to airflow and reduced single-breath diffusing capacity. Chest radiograph and computed tomography characteristically demonstrated diffuse interstitial infiltrates with cystic changes. Two asymptomatic patients with mild pulmonary involvement have remained in stable condition without hormonal therapy. The remaining seven patients had moderate to severe airflow obstruction; of these, five underwent hormonal therapy. Three patients had a clinical response to treatment. Two patients who did not receive hormonal treatment died of progressive respiratory failure. Most patients with pulmonary involvement in tuberous sclerosis have a slowly declining clinical course. Although the available data are limited, they suggest that a trial of hormonal therapy is recommended both for symptomatic patients and for those with declining pulmonary function. Tuberous sclerosis complex should be suspected in all patients with the diagnosis of lymphangioleiomyomatosis.
Key Words: lung • lymphangioleiomyomatosis • pulmonary • function • tuberous sclerosis
Submitted on March 29, 1993
Accepted on May 11, 1994
This article has been cited by other articles:
|
|
 |
|
  N. El-Hashemite and D. J. Kwiatkowski Interferon-{gamma}-Jak-Stat Signaling in Pulmonary Lymphangioleiomyomatosis and Renal Angiomyolipoma: A Potential Therapeutic Target Am. J. Respir. Cell Mol. Biol., September 1, 2005; 33(3): 227 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Abbott, M. L. Rosado-de-Christenson, A. A. Frazier, T. J. Franks, R. D. Pugatch, and J. R. Galvin From the Archives of the AFIP: Lymphangioleiomyomatosis: Radiologic-Pathologic Correlation RadioGraphics, May 1, 2005; 25(3): 803 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. El-Hashemite, V. Walker, and D. J. Kwiatkowski Estrogen Enhances whereas Tamoxifen Retards Development of Tsc Mouse Liver Hemangioma: A Tumor Related to Renal Angiomyolipoma and Pulmonary Lymphangioleiomyomatosis Cancer Res., March 15, 2005; 65(6): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yu, A. Astrinidis, S. Howard, and E. P. Henske Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L694 - L700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Lonergan and J. G. Smirniotopoulos Case 64: Tuberous Sclerosis Radiology, November 1, 2003; 229(2): 385 - 388. [Full Text] [PDF]
|
|
|
|
 |
|
 C I Whale, S R Johnson, K G Phillips, S A Newton, S A Lewis, and A E Tattersfield Lymphangioleiomyomatosis: a case-control study of perinatal and early life events Thorax, November 1, 2003; 58(11): 979 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Halabi, R. Convery, and J. M. Curtis Progressive Dyspnea in a 49-Year-Old Woman With Long-standing Epilepsy* Chest, July 1, 2002; 122(1): 352 - 355. [Full Text] [PDF]
|
|
|
|
|
|
G. Pacheco-Rodriguez, A. S. Kristof, L. A. Stevens, Y. Zhang, D. Crooks, and J. Moss Genetics and Gene Expression in Lymphangioleiomyomatosis : Giles F. Filley Lecture Chest, March 1, 2002; 121(2007): 56S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. FRANZ, A. BRODY, C. MEYER, J. LEONARD, G. CHUCK, S. DABORA, G. SETHURAMAN, T. V. COLBY, D. J. KWIATKOWSKI, and F. X. MCCORMACK Mutational and Radiographic Analysis of Pulmonary Disease Consistent with Lymphangioleiomyomatosis and Micronodular Pneumocyte Hyperplasia in Women with Tuberous Sclerosis Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. MOSS, N. A. AVILA, P. M. BARNES, R. A. LITZENBERGER, J. BECHTLE, P. G. BROOKS, C. J. HEDIN, S. HUNSBERGER, and A. S. KRISTOF Prevalence and Clinical Characteristics of Lymphangioleiomyomatosis (LAM) in Patients with Tuberous Sclerosis Complex Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 669 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. STRIZHEVA, T. CARSILLO, W. D. KRUGER, E. J. SULLIVAN, J. H. RYU, and E. P. HENSKE The Spectrum of Mutations in TSC1 and TSC2 in Women with Tuberous Sclerosis and Lymphangiomyomatosis Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 253 - 258. [Abstract] [Full Text]
|
|
|
|
|
|
S R Johnson and A E Tattersfield Clinical experience of lymphangioleiomyomatosis in the UK Thorax, December 1, 2000; 55(12): 1052 - 1057. [Abstract] [Full Text]
|
|
|
|
|
|
M.-C. AUBRY, J. L. MYERS, J. H. RYU, E. P. HENSKE, H. LOGGINIDOU, S. M. JALAL, and H. D. TAZELAAR Pulmonary Lymphangioleiomyomatosis in a Man Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 749 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Carsillo, A. Astrinidis, and E. P. Henske Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis PNAS, May 23, 2000; 97(11): 6085 - 6090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Hyman and V. H. Whittemore National Institutes of Health Consensus Conference: Tuberous Sclerosis Complex Arch Neurol, May 1, 2000; 57(5): 662 - 665. [Full Text] [PDF]
|
|
|
|
|
|
H. Logginidou, X. Ao, I. Russo, and E. P. Henske Frequent Estrogen and Progesterone Receptor Immunoreactivity in Renal Angiomyolipomas From Women With Pulmonary Lymphangioleiomyomatosis* Chest, January 1, 2000; 117(1): 25 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Astrinidis, L. Khare, T. Carsillo, T. Smolarek, K.-S. Au, H. Northrup, and E. P. Henske Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis J. Med. Genet., January 1, 2000; 37(1): 55 - 57. [Abstract] [Full Text]
|
|
|
|
 |
|
 Baron and A. Barkovich MR Imaging of Tuberous Sclerosis in Neonates and Young AJNR Am. J. Neuroradiol., May 1, 1999; 20(5): 907 - 916. [Abstract] [Full Text]
|
|
|
|
|
|
S. C. Chu, K. Horiba, J. Usuki, N. A. Avila, C. C. Chen, W. D. Travis, V. J. Ferrans, and J. Moss Comprehensive Evaluation of 35 Patients With Lymphangioleiomyomatosis Chest, April 1, 1999; 115(4): 1041 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Johnson Rare diseases bullet 1: Lymphangioleiomyomatosis: clinical features, management and basic mechanisms Thorax, March 1, 1999; 54(3): 254 - 264. [Full Text]
|
|
|
|
|
|
Report of Workshop on Lymphangioleiomyomatosis Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 679 - 683. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
